These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26808827)

  • 41. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
    Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
    Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.
    Stifano G; Sornasse T; Rice LM; Na L; Chen-Harris H; Khanna D; Jahreis A; Zhang Y; Siegel J; Lafyatis R
    Arthritis Rheumatol; 2018 Jun; 70(6):912-919. PubMed ID: 29858547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
    Sircar G; Goswami RP; Sircar D; Ghosh A; Ghosh P
    Rheumatology (Oxford); 2018 Dec; 57(12):2106-2113. PubMed ID: 30053212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.
    Zheng B; Nevskaya T; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Feb; 59(2):398-406. PubMed ID: 31359048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
    Herrick AL; Lunt M; Whidby N; Ennis H; Silman A; McHugh N; Denton CP
    J Rheumatol; 2010 Jan; 37(1):116-24. PubMed ID: 19955050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
    Kaldas M; Khanna PP; Furst DE; Clements PJ; Kee Wong W; Seibold JR; Postlethwaite AE; Khanna D;
    Rheumatology (Oxford); 2009 Sep; 48(9):1143-6. PubMed ID: 19605370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
    Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
    Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
    J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid skin thickness progression rate is associated with high incidence rate of cardiopulmonary complications in patients with early diffuse cutaneous systemic sclerosis: inception cohort study.
    Wangkaew S; Thongwitokomarn H; Prasertwittayakij N; Euathrongchit J
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):98-105. PubMed ID: 32865165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
    Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
    Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
    Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
    Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy.
    Paone C; Chiarolanza I; Cuomo G; Ruocco L; Vettori S; Menegozzo M; La Montagna G; Valentini G
    Clin Exp Rheumatol; 2007; 25(4):613-6. PubMed ID: 17888219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria
    Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
    Khanna D; Furst DE; Hays RD; Park GS; Wong WK; Seibold JR; Mayes MD; White B; Wigley FF; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally EV; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
    Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
    Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hearing loss in diffuse cutaneous systemic scleroderma.
    Monteiro TA; Christmann RB; Bonfá E; Bento RF; Novalo-Goto ES; Vasconcelos LG
    Scand J Rheumatol; 2011 Nov; 40(6):467-71. PubMed ID: 21916804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
    Clements PJ; Seibold JR; Furst DE; Mayes M; White B; Wigley F; Weisman MD; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Wong WK
    Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.